Company Watch

Suven secures two product patents in China and Russia

Our News Bureau - Mumbai

Suven Life Sciences (Suven) announced that two product patents were granted in China (100378108 and 100378109) and Russia (2325392 and 2340619) corresponding to two of their new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid until 2023 and 2024 respectively.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer's disease, Attention Deficient Hyperactivity Ddisorder (ADHD), Huntington's disease, Parkinson and schizophrenia.

These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.

"We are very pleased by the grant of these patents to Suven by the patent offices of China and Russia for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $20 billion market potential globally" said Venkat Jasti, CEO, Suven.

The company has six internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and schizophrenia.